ADVERTISEMENT

Zydus Cadila's Covid Vaccine Approval To Take Few More Days: Report

Zydus-Cadila COVID-19 Vaccine: The Subject Expert Committee is expected to meet this week and review the data.

Updated
<div class="paragraphs"><p>Zydus Cadila COVID-19 Vaccine: This will be the fifth COVID-19 vaccine to get approval in India</p></div>
i

The approval of Zydus Cadila's COVID-19 vaccine, for those aged 12 years and above, might take a few more days, news agency ANI reported quoting sources.

The Subject Expert Committee (SEC) is expected to meet this week and review the data submitted by the company. "Final approval for emergency use authorisation (EUA) will be given only after a few meetings," the source was quoted as saying by ANI.

The Gujarat-based pharmaceutical major had sought emergency use approval of the DNA vaccine against COVID-19, ZyCoV-D, for everyone above the age of 12, on 1 July, from the Drugs Controller General of India.

The company had presented the interim results of the phase 3 trials that showed that vaccine has an efficacy of 66.6 percent in preventing symptomatic illness and a 100 percent efficacy when it comes to moderate illness.

ADVERTISEMENT

Phase 3 Trials: What Is the Vaccine's Efficacy

  • 66.6 percent in preventing symptomatic illness

  • 100 percent when it comes to moderate illness

What Else Do We Know From Phase 3 Trials?

The double blind placebo trial involved 28000 participants in 50 clinics across India. Out of this, around 1000 of them were children aged between 12-18.

No moderate or severe cases of covid were observed in the vaccine sub group of the trial.

If approved, the 3 dose Covid vaccine, will be the world's first plasmid DNA COVID vaccine to be given approval.

This will be the fifth COVID-19 vaccine to get approval in India after Covishield, Covaxin, Sputnik V and Moderna.

It will also be the first vaccine to get a nod for children.

(Subscribe to FIT on Telegram)

Published: 
ADVERTISEMENT
Stay Up On Your Health

Subscribe To Our Daily Newsletter Now.

Join over 120,000 subscribers!
ADVERTISEMENT